Toward defining the clinically actionable genome of metastatic breast cancer.

Genomics-guided therapies are transforming oncology, but selecting patients who are candidates for drugs matched to their tumor's biological profile is difficult.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 have shown in a randomized clinical trial that a standardized system for determining the actionability of genomic alterations identifies breast cancer patients who significantly benefit from molecularly targeted agents.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: